Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - 31/12/20

Doi : 10.1016/S1470-2045(20)30540-4

Stephen A Boorjian, ProfMD ^a, Mehrdad Alemozaffar, MD ^b, Badrinath R Konety, ProfMD ^c, Neal D Shore, MD ^d, Leonard G Gomella, ProfMD ^e, Ashish M Kamat, ProfMD ^f, Trinity J Bivalacqua, ProfMD ^g, Jeffrey S Montgomery, ProfMD ^h, Seth P Lerner, ProfMD ⁱ, Joseph E Busby, MD ^j, Michael Poch, MD ^k, Paul L Crispen, MD ^l, Gary D Steinberg, ProfMD ^m, Anne K Schuckman, MD ⁿ, Tracy M Downs, ProfMD ^o, Robert S Svatek, ProfMD ^p, Joseph Mashni, MD ^q, Brian R Lane, MD ^r, Thomas J Guzzo, ProfMD ^s, Gennady Bratslavsky, ProfMD ^t, Lawrence I Karsh, MD ^u, Michael E Woods, MD ^v, Gordon Brown, DO ^w, Daniel Canter, MD ^x, Adam Luchey, MD ^y, Yair Lotan, ProfMD ^z, Tracey Krupski, MD ^aa, Brant A Inman, MD ^ab, Michael B Williams, MD ^ac, Michael S Cookson, ProfMD ^ad, Kirk A Keegan, MD ^ae, Gerald L Andriole, ProfMD ^af, Alexander I Sankin, MD ^ag, Alan Boyd, ProfMD ^ah, Michael A O’Donnell, ProfMD ^ai, David Sawutz, PhD ^aj, Richard Philipson, MD ^ak, Ruth Coll, BSc ^ak, Vikram M Narayan, MD ^f, F Peter Treasure, PhD ^al, Seppo Yla-Herttuala, ProfMD ^am, Nigel R Parker, PhD ^am, Colin P N Dinney, ProfMD ^f,⁎

^a Department of Urology, Mayo Clinic, Rochester, MN, USA

^b Department of Urology, Kaiser Permanente Los Angeles, Los Angeles, CA, USA

^c Department of Urology, University of Minnesota, Minneapolis, MN, USA

^d Carolina Urologic Research Center, Myrtle Beach, SC, USA

^e Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

^f Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

^g Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA

^h Department of Urology, University of Michigan, Ann Arbor, MI, USA

ⁱ Scott Department of Urology, Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, TX, USA

^j Cancer Centers of the Carolinas, Greenville Hospital System, Greenville, SC, USA

^k Department of GU Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA

^l Department of Urology, University of Florida, Gainesville, FL, USA

^m Department of Urology, New York University Langone Health, New York, NY, USA

ⁿ USC Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

^o Department of Urology, University of Wisconsin, Madison, WI, USA

^p Department of Urology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

^q Banner MD Anderson Cancer Center, Gilbert, AZ, USA

^r Division of Urology, Spectrum Health, Michigan State University College of Human Medicine, Grand Rapids, MI, USA

^s Division of Urology, University of Pennsylvania, Philadelphia, PA, USA

^t Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA

^u The Urology Center of Colorado, Denver, CO, USA

^v Department of Urology, University of North Carolina, Chapel Hill, NC, USA

^w New Jersey Urology, Bloomfield, NJ, USA

^x Ochsner Health System, Jefferson, LA, USA

^y West Virginia University Cancer Institute, Morgantown, WV, USA

^z Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA

^aa Department of Urology, University of Virginia Cancer Center, Charlottesville, VA, USA

^ab Division of Urology, Department of Surgery, Duke University School of Medicine, Durham, NC, USA

^ac Urology of Virginia, Virginia Beach, VA, USA

^ad Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

^ae Department of Urology, Vanderbilt University Medical Center, Nashville, TN, USA

^af Washington University School of Medicine in St Louis, St Louis, MO, USA

^ag Department of Urology, Montefiore Medical Center, Bronx, NY, USA

^ah Alan Boyd Consultants, Crewe, UK

^ai Department of Urology, University of Iowa, Iowa City, IA, USA

^aj FKD Therapies Oy, Kuopio, Finland

^ak Trizell, Chinnor, Oxon, UK

^al Peter Treasure Statistical Services, King’s Lynn, UK

^am AI Virtanen Institute University of Eastern Finland and Science Service Center and Gene Therapy Unit, Kuopio, Finland

^* Correspondence to: Prof Colin P N Dinney, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA Department of Urology Division of Surgery University of Texas MD Anderson Cancer Center Houston TX 77030 USA

Summary

Background

BCG is the most effective therapy for high-risk non-muscle-invasive bladder cancer. Nadofaragene firadenovec (also known as rAd-IFNa/Syn3) is a replication-deficient recombinant adenovirus that delivers human interferon alfa-2b cDNA into the bladder epithelium, and a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. We aimed to evaluate its efficacy in patients with BCG-unresponsive non-muscle-invasive bladder cancer.

Methods

In this phase 3, multicentre, open-label, repeat-dose study done in 33 centres (hospitals and clinics) in the USA, we recruited patients aged 18 years or older, with BCG-unresponsive non-muscle-invasive bladder cancer and an Eastern Cooperative Oncology Group status of 2 or less. Patients were excluded if they had upper urinary tract disease, urothelial carcinoma within the prostatic urethra, lymphovascular invasion, micropapillary disease, or hydronephrosis. Eligible patients received a single intravesical 75 mL dose of nadofaragene firadenovec (3 × 10¹¹ viral particles per mL). Repeat dosing at months 3, 6, and 9 was done in the absence of high-grade recurrence. The primary endpoint was complete response at any time in patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour). The null hypothesis specified a complete response rate of less than 27% in this cohort. Efficacy analyses were done on the per-protocol population, to include only patients strictly meeting the BCG-unresponsive definition. Safety analyses were done in all patients who received at least one dose of treatment. The study is ongoing, with a planned 4-year treatment and monitoring phase. This study is registered with ClinicalTrials.gov, NCT02773849.

Findings

Between Sept 19, 2016, and May 24, 2019, 198 patients were assessed for eligibility. 41 patients were excluded, and 157 were enrolled and received at least one dose of the study drug. Six patients did not meet the definition of BCG-unresponsive non-muscle-invasive bladder cancer and were therefore excluded from efficacy analyses; the remaining 151 patients were included in the per-protocol efficacy analyses. 55 (53·4%) of 103 patients with carcinoma in situ (with or without a high-grade Ta or T1 tumour) had a complete response within 3 months of the first dose and this response was maintained in 25 (45·5%) of 55 patients at 12 months. Micturition urgency was the most common grade 3–4 study drug-related adverse event (two [1%] of 157 patients, both grade 3), and there were no treatment-related deaths.

Interpretation

Intravesical nadofaragene firadenovec was efficacious, with a favourable benefit:risk ratio, in patients with BCG-unresponsive non-muscle-invasive bladder cancer. This represents a novel treatment option in a therapeutically challenging disease state.

Funding

FKD Therapies Oy.

Le texte complet de cet article est disponible en PDF.

Plan

Introduction

Methods

Study design and participants

Procedures

Outcomes

Statistical analysis

Role of the funding source

Results

Discussion

Data sharing

Export

Vol 22 - N° 1

P. 107-117 - janvier 2021 Retour au numéro

Article précédent

Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study
Anastasia Chalkidou, Thomas Macmillan, Mariusz T Grzeda, Janet Peacock, Jennifer Summers, Saskia Eddy, Bola Coker, Hannah Patrick, Helen Powell, Lee Berry, Gareth Webster, Peter Ostler, Peter D Dickinson, Matthew Q Hatton, Ann Henry, Stephen Keevil, Maria A Hawkins, Nick Slevin, Nicholas van As

| Article suivant

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
Mark H O’Hara, Eileen M O’Reilly, Gauri Varadhachary, Robert A Wolff, Zev A Wainberg, Andrew H Ko, George Fisher, Osama Rahma, Jaclyn P Lyman, Christopher R Cabanski, Rosemarie Mick, Pier Federico Gherardini, Lacey J Kitch, Jingying Xu, Theresa Samuel, Joyson Karakunnel, Justin Fairchild, Samantha Bucktrout, Theresa M LaVallee, Cheryl Selinsky, Jacob E Till, Erica L Carpenter, Cécile Alanio, Katelyn T Byrne, Richard O Chen, Ovid C Trifan, Ute Dugan, Christine Horak, Vanessa M Hubbard-Lucey, E John Wherry, Ramy Ibrahim, Robert H Vonderheide

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial - 31/12/20

Summary

Background

Methods

Findings

Interpretation

Funding

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL